MedinCell Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Christophe Douat
Chief executive officer
€521.8k
Total compensation
| CEO salary percentage | 51.2% |
| CEO tenure | 9.3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.5yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | €522k | €267k | -€32m |
| Dec 31 2022 | n/a | n/a | -€29m |
| Sep 30 2022 | n/a | n/a | -€27m |
| Jun 30 2022 | n/a | n/a | -€26m |
| Mar 31 2022 | €329k | €258k | -€25m |
| Dec 31 2021 | n/a | n/a | -€22m |
| Sep 30 2021 | n/a | n/a | -€20m |
| Jun 30 2021 | n/a | n/a | -€19m |
| Mar 31 2021 | €336k | €235k | -€19m |
| Dec 31 2020 | n/a | n/a | -€22m |
| Sep 30 2020 | n/a | n/a | -€26m |
| Jun 30 2020 | n/a | n/a | -€25m |
| Mar 31 2020 | €301k | €232k | -€24m |
| Dec 31 2019 | n/a | n/a | -€21m |
| Sep 30 2019 | n/a | n/a | -€19m |
| Jun 30 2019 | n/a | n/a | -€19m |
| Mar 31 2019 | €244k | €192k | -€20m |
| Dec 31 2018 | n/a | n/a | -€17m |
| Sep 30 2018 | n/a | n/a | -€15m |
| Jun 30 2018 | n/a | n/a | -€12m |
| Mar 31 2018 | €175k | €149k | -€10m |
| Mar 31 2017 | €151k | €128k | -€4m |
Compensation vs Market: Christophe's total compensation ($USD551.38K) is below average for companies of similar size in the US market ($USD1.55M).
Compensation vs Earnings: Christophe's compensation has increased whilst the company is unprofitable.
CEO
Christophe Douat (57 yo)
9.3yrs
Tenure
€521,830
Compensation
Mr. Christophe Douat serves as Chairman of the Management Board and Chief Executive officer at MedinCell S.A and served as General Manager. Mr. Douat serves as an Investment Director of Matignon Investisse...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Executive Board | 9.3yrs | €521.83k | no data | |
| CFO & Member of Executive Board | no data | €323.49k | no data | |
| Chief People Officer & Member of the Management Board | 3.5yrs | €270.86k | no data | |
| Head of Communication & IR | no data | no data | no data | |
| Head of Legal | 2.8yrs | no data | no data | |
| Head of Research & Development | no data | no data | no data | |
| Chief Business Officer | 1.8yrs | no data | no data | |
| Head of Strategic Alliance Management | 4.3yrs | no data | no data | |
| Head of Portfolio | 6.9yrs | no data | no data | |
| Chief Medical Officer | 1.5yrs | no data | no data | |
| Head of Pharmaceutical Operations | no data | no data | no data | |
| Senior Communications Officer | no data | no data | no data |
3.5yrs
Average Tenure
Experienced Management: MDCL.F's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President of the Supervisory Board | 9.3yrs | €118.75k | 6.7% $ 11.9m | |
| Supervisory Board Member | 1.3yrs | €55.18k | no data | |
| Independent Vice-Chairman of Supervisory Board | 6.3yrs | €25.00k | no data | |
| Independent Member of Supervisory Board | 12.9yrs | €60.60k | no data | |
| Independent Member of Supervisory Board | 7.4yrs | €46.30k | no data | |
| Censor | no data | no data | no data | |
| Supervisory Board Member | 2.8yrs | €47.88k | no data |
6.8yrs
Average Tenure
Experienced Board: MDCL.F's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/28 16:44 |
| End of Day Share Price | 2023/07/31 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MedinCell S.A. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexandru Cogut | Bryan Garnier & Co |
| Oscar Haffen Lamm | Bryan Garnier & Co |
| Raghuram Selvaraju | H.C. Wainwright & Co. |